Who
Cameron Turtle
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Spyre Therapeutics; Director, Damora Therapeutics; Director, Oruka Therapeutics; Chief Business Officer, Eidos Therapeutics; Officer, BridgeBio Pharma.
In numbers
- Trades disclosed
- 201
- Buys
- 0
- Sells
- 37
- Bought
- $0
- Sold
- $31.7M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 30 Nov 2018
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K600 at $89.14 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $242K2,683 at $90.10 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $241K2,638 at $91.49 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $368K3,989 at $92.31 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $466K4,990 at $93.37 | filing |
| 1 Oct 2026filed 2 Oct 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,391100 at $93.91 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $216K2,500 at $86.36 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $732K8,400 at $87.15 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $326K3,700 at $88.06 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K400 at $89.07 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $216K2,500 at $86.36 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $732K8,400 at $87.15 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $326K3,700 at $88.06 | filing |
| 1 Sep 2026filed 3 Sep 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $36K400 at $89.07 | filing |
| 3 Aug 2026filed 5 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K800 at $93.97 | filing |
| 3 Aug 2026filed 5 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $681K7,157 at $95.10 | filing |
| 3 Aug 2026filed 5 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $541K5,635 at $95.93 | filing |
| 3 Aug 2026filed 5 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $135K1,392 at $96.82 | filing |
| 3 Aug 2026filed 5 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,55916 at $97.46 | filing |
| 3 Aug 2026filed 5 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K800 at $93.97 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Cameron Turtle; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.